Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Thursday, March 28, 2024 | Back issues
Courthouse News Service Courthouse News Service

Shareholder Derivative

SAN FRANCISCO - Directors propped up the share price of Dynavax Technologies by misrepresenting prospects of its Heplisav hepatitis B drug, and the share price dropped by 69% when the truth came out, shareholders claim in a derivative complaint.

Categories / Uncategorized

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...